These findings suggest that TP53 pathway activation is associated with enhanced venetoclax-induced apoptosis with the downregulation of DRP1 expression, and mutated TP53 allows DRP1 to remain upregulated in the TP53mut AML cells. This evidence concerns the gene DNM1L and acute myeloid leukemia.